Aquestive Therapeutics, Inc. (AQST)

4.23 0.00 (0.00%) USD  |  NASDAQ  |  May 07, 16:00
4.24 +0.01 (+0.24%) Pre-Market: 20:00
More

Aquestive Therapeutics Research and Development Expense (Annual) : 17.19M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for AQST.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Nektar Therapeutics 117.07M
REGENXBIO, Inc. 212.68M
Verastem, Inc. 114.60M
Harrow, Inc. 12.85M
ACADIA Pharmaceuticals, Inc. 328.80M